Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial - Bergmann, Lothar; Albiges, L.; Ahrens, M.; Gross-Goupil, M.; Boleti, E.; Gravis, G.; Fléchon, A.; Grimm, M. -O.; Bedke, J.; Barthélémy, P.; Castellano, D.; Mellado, B.; et al. (Annals of oncology, 2025)
Online verfügbar: 1. April 2025, Artikelversion: 13. Juni 2025